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Elevating microRNA-122 in blood
improves outcomes after temporary
middle cerebral artery occlusion in rats
Da Zhi Liu, Glen C Jickling, Bradley P Ander, Heather Hull,
Xinhua Zhan, Christopher Cox, Natasha Shroff,
Cheryl Dykstra-Aiello, Boryana Stamova and Frank R Sharp
Abstract
Because our recent studies have demonstrated that miR-122 decreased in whole blood of patients and in whole blood of
rats following ischemic stroke, we tested whether elevating blood miR-122 would improve stroke outcomes in rats.
Young adult rats were subjected to a temporary middle cerebral artery occlusion (MCAO) or sham operation. A
polyethylene glycol-liposome-based transfection system was used to administer a miR-122 mimic after MCAO.
Neurological deficits, brain infarction, brain vessel integrity, adhesion molecule expression and expression of miR-122
target and indirect-target genes were examined in blood at 24 h after MCAO with or without miR-122 treatment.
miR-122 decreased in blood after MCAO, whereas miR-122 mimic elevated miR-122 in blood 24 h after MCAO.
Intravenous but not intracerebroventricular injection of miR-122 mimic decreased neurological deficits and brain infarc-
tion, attenuated ICAM-1 expression, and maintained vessel integrity after MCAO. The miR-122 mimic also down-
regulated direct target genes (e.g. Vcam1, Nos2, Pla2g2a) and indirect target genes (e.g. Alox5, Itga2b, Timp3, Il1b,
Il2, Mmp8) in blood after MCAO which are predicted to affect cell adhesion, diapedesis, leukocyte extravasation,
eicosanoid and atherosclerosis signaling. The data show that elevating miR-122 improves stroke outcomes and we
postulate this occurs via downregulating miR-122 target genes in blood leukocytes.
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Introduction
Though a large number of compounds are effective in
animal models of stroke, testing in human clinical
stroke trials has not produced any treatments other
than tissue plasminogen activator (tPA) for acute ische-
mic stroke. Such translational failures have been
ascribed to various issues including animal models,
experimental rigor, clinical trial designs and stroke het-
erogeneity. One potential contributor might be that
drug development efforts for stroke have focused on
small molecules that target a single gene, protein, or
enzyme. Since ischemic tissue might die via many par-
allel pathways, blocking just one or two pathways may
not be effective. A ‘‘cocktail approach’’ and agents with
multiple mechanisms of action have been suggested,1
but determining the optimum combination of therapies
has been a challenge.2,3
These facts led us to consider miRNAs as a treat-
ment for stroke in part because a single miRNA can
modulate dozens to hundreds of target messenger
RNAs (mRNA) by inducing mRNA degradation or
blocking protein translation.4 Since the initial discovery
of miRNAs in the early 1990s,5,6 they have emerged as
biomarkers for diagnosis and treatment of a large var-
iety of diseases, including hepatitis, asthma, cancer and
stroke.7–9 Moreover, there are now a number of reports
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showing that modulating miRNA (e.g. miR-497, Let 7f,
miR-181, miR-15b, miR-30a, miR-23a-3p, miR-134,
miR-200c, miR-424) can decrease brain infarction and
attenuate behavioral deficits after cerebral ischemia in
rodents.10–20 Moreover, increasing miR-133b in multi-
potent mesenchymal stromal cells (MSCs) promotes
plasticity and functional recovery at 24 h after MCAO
in rats.21 Another promising feature of microRNA is
that two miRNA drugs have already been advanced to
human trials including a microRNA-122 (miR-122)
inhibitor that treats hepatitis C infection22 and a
miR-34a mimic that treats cancer in humans.23 Thus,
miRNA-based therapeutics are feasible.
When we began to examine miRNA for the treat-
ment of stroke, the question arose as to which of the
>1000 miRNAs in the human genome might be the
best candidates. To address this question, we proposed
the following approach: miRNAs that are similarly
regulated in blood of both rodents and in humans
might be good targets to study as possible treatments
for stroke. Our recent findings demonstrated that miR-
122 was decreased in blood of ischemic stroke patients9
and in the blood of ischemic rats.8 In the current study,
we confirm that miR-122 decreases in blood after
MCAO in rats. This might make it more likely that
results obtained in the rodent stroke models would
apply to human stroke. Since the miR-122 sequence is
conserved between vertebrate species, this also makes
miR-122 a promising candidate for translation from
rodent stroke models to human stroke.
In this study, we tested whether elevating blood
miR-122 has the potential for treating stroke. Using a
newly developed in vivo polyethylene glycol 2000
(PEG)-liposome based miRNA transfection system
and the rat suture MCAO model, we show that intra-
venous (i.v.), but not intracerebroventricular (i.c.v.)
injection of miR-122 mimic after MCAO dose-depen-
dently improves stroke outcomes.
Materials and methods
Ischemic stroke model
Ischemic stroke was produced using the suture MCAO
method.24,25Male Sprague-Dawley rats, at the age of
7–8 weeks, were anesthetized with isoflurane (Minrad,
New York, NY, USA). A silicon-coated suture (Doccol
Corporation, MA, USA) was introduced into the exter-
nal carotid artery and advanced up the internal carotid
artery to the Circle of Willis, where it blocks the origin
of the MCA24 to decrease blood flow of this artery for
1.5 h. Occlusions were confirmed by laser Doppler
showing cerebral blood flow decreased to at least
20% of baseline during the 1.5 h occlusion.
Measurements of physiological variables including
temperature, pulse, blood pressure, respiratory rate,
and blood gases showed no differences between the
groups (not shown). Prior to the study, rats were
blindly randomized to either sham surgery or MCAO
surgery; and for each of these groups, they were further
blindly randomized to receive either miR-122 mimic or
scrambled sequence of miR-122 mimic as a control.
After closure of the operative sites, rats were allowed
to recover in an incubator maintained at 37C, and then
returned to their home cages with free access to food and
water. They were allowed to survive for 22.5 h after the
1.5-h MCAO. All experimental procedures were per-
formed in accordance with National Institutes of Health
guidelines and were approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of
California at Davis. The manuscript was written up in
compliance with the ARRIVE guidelines.
TaqMan miRNA assay of miR-122 expression in
blood after MCAO
Male Sprague-Dawley rats (n¼ 24), at the age of 7–8
weeks, were divided into four groups (six rats/group).
These included a sham operation group, and three
groups of MCAO rats treated intravenously with
scrambled miRNA mimic (2.4mg/kg, i.v.) or miR-122
mimic (0.6mg/kg and 2.4mg/kg, i.v.) given within
5min after the MCAO. Scrambled miRNA mimic
and miR-122 mimic were wrapped using PEG-
liposomes and administered through the tail vein imme-
diately after MCAO.
Whole blood was collected 24 h after MCAO in
PAXgene tubes (Pre-AnalytiX) to lyse all leukocytes
and other cells in blood and to also immediately stabil-
ize RNA. Total RNA (including miRNA) was isolated
from PAXgene tubes as previously described.9 The con-
centration and integrity of the total RNA were deter-
mined using a NanoDrop-1000 spectrophotometer
(Thermo Scientific, DE, USA) and Agilent-2100
Bioanalyzer (Agilent Technologies, CA, USA). RNA
samples had a purity ratio of 28 s/18 s rRNA equal
to or better than 1.8 and an A260/A280 absorbance
ratio greater than 2.0. A TaqMan miR-122 assay
(Life Technology, CA, USA) was employed to detect
expression of miR-122 using a 7900HT real-time PCR
instrument. The U6 miRNA was used as the endogen-
ous control. Each group included three replicates
(n¼ 6). Statistical differences were determined using
ANOVA followed by Dunnett’s post hoc test.
Animal groups and miRNA administration after
MCAO
Male Sprague-Dawley rats (n¼ 30), at the age of 7–8
weeks, were divided into five groups (six rats/group).
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Scrambled miRNA mimic and miR-122 mimic were
wrapped using PEG-liposomes prior to administra-
tion (i.v. or i.c.v.) after MCAO. The groups
included a sham operation group and three MCAO
groups treated intravenously with scrambled
miRNA mimic (2.4mg/kg, i.v.) or miR-122 mimic
(0.6mg/kg and 2.4mg/kg, i.v.) given within 5min
after MCAO. An additional group had the miR-
122 mimic (0.6mg/kg, i.c.v.) given intracerebroventri-
cularly through a pre-drilled skull hole into the left
lateral cerebral ventricles (coordinates: 0.9mm
caudal, 1.4mm lateral, and 4.6mm deep with
respect to bregma) within 5min after the MCAO
while animals were still anesthetized. Behavioral
evaluations, infarct measurements, and all analyses
were performed by an investigator blinded to the
treatment groups.
Assessment of neurological impairment
Neurological impairment was examined between 22
and 24 h after MCAO according to our previous meth-
ods.24 Briefly, forelimb flexion, spontaneous rotation,
and absence of response to contralateral whisker stimu-
lation were scored on a 0–2 scale (0 – normal behavior;
1 – moderate impairment; and 2 – severely impaired).
Statistical tests used the non-parametric Kruskal–
Wallis test. Testing was performed by an investigator
blinded to the treatment status.
Cresyl Violet staining and measurement of brain
infarction
At 24-h post MCAO animals were anesthetized
and euthanized. Brains were removed and
processed for Cresyl Violet staining.26 Brain sections
were scanned, and infarcted and healthy tissues were
measured using an image analysis system (Adobe
Photoshop).24 Statistical tests used an ANOVA fol-
lowed by Dunnett’s post hoc test. Measurements were
performed by an investigator blinded to the treatment
status.
Immunohistochemistry-double labeling for ICAM-1
and vWF
Formaldehyde-fixed brain sections were incubated
with primary antibodies to mouse anti-ICAM-1
(1:200, Abcam, MA, USA) and rabbit anti-
vonWillebrandt Factor (vWF) (1:200, Abcam, MA,
USA). Species-specific IgG, conjugated to Alexa 594
or 488 (1:1,000; Life Technology, CA, USA), were
used as secondary antibodies. Controls had the primary
antibody deleted.
TaqMan qRT-PCR array to profile the expression of
miR-122 target genes in blood after MCAO with or
without the miR-122 treatment
Blood was collected via cardiac puncture 24 hours after
MCAO, and total RNA was isolated and amount and
purity quantified according to our previous protocols.9
TaqMan custom mRNA 384-well fluidic cards
(Supplemental Table 1 showing the plate layout, Life
Technology, CA, USA) were used to profile gene
expression in blood. A list of the genes tested by
qRT-PCR is provided in Supplemental Table 1. This
list was compiled based upon known miR-122 target
genes, genes known to be regulated by miR-122 target
genes (indirect target genes) and genes implicated in
stroke but not known to be miR-122 direct or indirect
target genes. The cards were run using a 7900HT real-
time PCR instrument. 18S was used as the endogenous
control. The statistical analyses were performed using
Partek Genomics Suite 6.4 (Partek, MI, USA), and dif-
ferentially expressed mRNAs in the group of MCAO/
miR-122 mimic were determined by student’s t-test, as
compared to the group of MCAO/scrambled miRNA
mimic. A p< 0.05 and fold change> W1.4W were con-
sidered significant.
Custom database of miR-122 target genes
To predict miR-122 target genes, we used two separate
publicly available miRNA-mRNA function algorithms,
TargetScan and miRanda. This generated a custom
database of 1120 predicted miR-122 target genes,
including many immune response- or stroke outcome-
related genes (e.g. Ccl22, Vcam1, Fkbp5, Il1rn, Il22ra2,
C1qb, Nos2, Clic4, Epo, Aldoa, Calpain 1, and others)
(Supplemental Table 2). A subgroup of these known
miR-122 target genes was measured by qRT-PCR as
described in the previous section.
Integrated miR-122, altered mRNA network and
functional analyses
The integrated functional network analyses for
miR-122 and altered mRNAs were performed accord-
ing to our methods described previously with minor
modifications.27 Briefly, the data list of significantly
down-regulated mRNAs, and the custom database of
miR-122 and its putative target genes were uploaded
into the integrated miRNA-mRNA functional network
analyses software: Exploratory Gene Association
Networks (EGAN). We expected that the genes
down-regulated by the miR-122 mimic after MCAO
could be divided into three groups: (1) known miR-
122 direct target genes – that were defined as those
with a mRNA sequence complementary to the
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miR-122 sequence; (2) miR-122 indirect target genes –
that were defined as those known to be regulated by
miR-122 target genes; and (3) novel miR-122 indirect
target genes – that were defined as those genes regulated
following miR-122 administration but had no sequence
homology to miR-122 and were not previously known
to be regulated by miR-122 direct or indirect target
mRNA. After the integrated miR-122 and target
genes networks were identified, a functional analysis
was performed on miR-122 direct and indirect genes
using Ingenuity Pathway Analysis (IPA).
Results
Effects of miR-122 mimic on miR-122 expression in
blood after MCAO
The TaqMan miRNA assay showed that miR-122
decreased in blood after MCAO (Figure 1). That is,
the miR-122 blood levels in sham-operated control ani-
mals were several fold more than in animals following
MCAO (treated with control scramble miRNA, left
panels of Figure 1). Intravenous administration of
miR-122 mimic (0.6mg/kg and 2.4mg/kg, i.v.) dose-
dependently elevated blood miR-122 after MCAO
compared to MCAO treated with control scramble
miRNA (*p< 0.05 for 2.4mg/kg i.v miR-122 mimic
vs. MCAO/scramble miRNA) (Figure 1). Though
blood levels of miR-122 increased nearly four-fold fol-
lowing 0.6mg/kg i.v. of miR-122 mimic compared to
scramble miRNA, this increase was not statistically sig-
nificant (Figure 1).
The effects of miR-122 mimic on behavioral out-
comes after MCAO
The behavioral results showed that the scramble
miRNA (control)-treated animals developed marked
behavioral deficits after MCAO (#p< 0.05 vs. sham),
while miR-122 mimic given i.v. (0.6, 2.4mg/kg, i.v.)
dose-dependently attenuated the MCAO-induced
behavioral deficits (Figure 2, *p< 0.05 for 2.4mg/kg
i.v. miR-122 mimic vs. MCAO/ scramble miRNA).
However, miR-122 mimic given intracerebroventricu-
larly (0.6mg/kg, i.c.v.) did not improve behavioral out-
comes (Figure 2).
The effects of miR-122 mimic on brain infarction
volumes after MCAO
Cresyl Violet histology showed that miR-122 mimic at
doses of 0.6mg/kg and 2.4mg/kg dose-dependently
attenuated the MCAO-induced brain infarction
volume (Figure 3(a) and (b), *p< 0.05, **p< 0.01 for
miR-122 mimic i.v. vs. MCAO/ scramble miRNA i.v.).
However, intracerebroventricular miR-122 mimic at a
dose of 0.6mg/kg, i.c.v. did not decrease infarction
volume (Figure 3(a) and (b)).
The effects of miR-122 mimic on blood brain barrier
integrity and adhesion molecule expression after
MCAO
In order to assess inflammation and integrity of brain
vessels, brain sections were double labeled with
Figure 1. miR-122 levels decreased in blood 24 h following
MCAO (Sham vs Scramble miRNA-MCAO). miR-122 mimic
given intravenously (0.6mg/kg and 2.4mg/kg i.v) elevates miR-122
levels in blood 24 h after MCAO in rats. Scrambled miRNA mimic
and miR-122 mimic were wrapped using PEG-liposomes prior to
intravenous administration after MCAO. miR-122 levels in blood
are shown on the Y axis. #p< 0.05 for scramble miRNA-MCAO
vs. sham. *p< 0.05 for miR-122 mimic-MCAO (2.4mg/kg) vs.
scramble miRNA-MCAO. n¼6/group.
Figure 2. miR-122 mimic given intravenously (0.6mg/kg and
2.4mg/kg i.v.) attenuates behavioral deficits after MCAO in rats,
but miR-122 mimic given intracerebroventricularly (0.6mg/kg
i.c.v.) does not. Scrambled miRNA mimic and miR-122 mimic
were wrapped using PEG-liposomes prior to i.v. or i.c.v. admin-
istration after MCAO. Neurological scores are shown on the Y
axis. #p< 0.05 for scramble miRNA-MCAO vs. sham; *p< 0.05
for miR-122 mimic-MCAO vs. scramble miRNA-MCAO. n¼ 6/
group.
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intercellular adhesion molecule 1 (ICAM-1, a marker
for immune cells and injured endothelial cells) and von
Willebrand factor (vWF, a marker for endothelial
cells). In sham-operated rats, the cerebral vessels had
an intact tube shape, and no ICAM-1 was expressed in
brain parenchyma and vessels (Figure 4(A) to (C)). In
scramble miRNA-treated MCAO animals, ICAM-1
was observed in brain parenchyma (Figure 4(E) and (F)),
and there was attenuation of the caliber of the vessels
in areas of infarction (Figure 4D). MiR-122 mimic
(2.4mg/kg, i.v.), given immediately after MCAO,
mostly prevented the MCAO-induced ICAM-1 expres-
sion in brain parenchyma (Figure 4(H) and (I)) and
maintained the caliber and tube shape of the vessels
(Figure 4(G) and (I)).
Predicted functions of genes down-regulated by miR-
122 mimic in blood after MCAO
TaqMan PCR arrays were used to detect gene expres-
sion after MCAO with or without miR-122 mimic
treatment. The data showed that miR-122 mimic
(2.4mg/kg, i.v.) down-regulated a number of genes in
blood after MCAO (p< 0.05 and fold change> W1.4W)
(Supplemental Table 3). In these functional assays, we
applied a relaxed cutoff (fold change> W1.4W but p> 0.05)
to include more down-regulated genes in blood after
MCAO (Supplemental Table 3). Using the
Exploratory Gene Association Networks (EGAN), we
classified the down-regulated genes into three sub-
groups as described in the Methods section: (1) miR-
122 direct target genes that included Vcam1, Nos2,
Pla2g2a, Ucp2, Clic4, and others (upper left panel in
Figure 5); (2) miR-122 indirect target genes that
included Alox5, Itga2b, Timp3, IL1b, IL2, MMP8,
and others (upper right panel in Figure 5); and (3)
miR-122 novel indirect target genes that included
Ltb4r2, Ifna1, Ilrapl2, Mmp11, Col4a2, Myl9, Mylk,
F2rl2, Thbs1 and others (lowest panel in Figure 5).
Using Ingenuity pathway analysis (IPA), we ana-
lyzed the functions of miR-122 direct and indirect
target genes. The top 5 ranked canonical pathways
included granulocyte/agranulocyte adhesion and diape-
desis, leukocyte extravasation, eicosanoid signaling and
atherosclerosis signaling (middle panel in Figure 5).
Discussion
This is the first study to show that administration of a
miR-122 mimic improves ischemic stroke outcomes. It
adds to a growing literature that many miRNA can
modulate ischemic brain injury at least in rodent
models.10–21 This proposal is unique in that it targeted
miR-122 because miR-122 decreased in whole blood
following both rat and human strokes,8,9 and miR-
122 improved ischemic stroke outcomes when injected
into blood but not when injected into brain.
In our previous human study, we showed that miR-
122 and many other miRNA decreased in whole blood
following ischemic stroke using both microarray and
PCR based methods.9 The miRNA described in that
study likely represent mostly intracellular miRNA
found in leukocytes, platelets, red blood cells, and
Figure 3. miR-122 mimic given intravenously (i.v.) but not
intracerebroventricularly (i.c.v.) decreases brain infarction after
MCAO in rats. Scrambled miRNA mimic and miR-122 mimic
were wrapped using PEG-liposomes prior to i.v. or i.c.v. admin-
istration after MCAO. (a) Cresyl Violet staining of coronal brain
sections from five different rats. Column 1 sections are from a
sham control. Column 2 sections are from scramble miRNA-
MCAO rats. Column 3 sections are from miR-122 mimic MCAO
(0.6mg/kg i.c.v.). Column 4 sections are from miR-122 mimic
MCAO (0.6mg/kg i.v.). Column 5 sections are from miR-122
mimic MCAO (2.4mg/kg i.v.). (b) Following MCAO, miR-122
mimic (0.6mg/kg i.v.) decreased infarction volume compared to
scramble miRNA (*p< 0.05) and miR-122 (2.4mg/kg i.v.) also
decreased infarction volume compared to scramble miRNA
(**p< 0.01). There was no significant difference of infarction
volume for miR-122 mimic (0.6mg/kg i.c.v) compared to scram-
ble miRNA 24 hours following MCAO. Infarction volumes are on
the Y-axis. *p< 0.05, **p< 0.01 for miR-122 mimic-MCAO vs.
scramble miRNA-MCAO. n¼ 6/group.
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other cells in whole blood since intracellular miRNA
levels are usually an order of magnitude or more higher
than extracellular miRNA levels in plasma or serum.9
However, miR-122 has been detected in plasma/serum
and reported to be altered in liver infections and liver
cancer.28 Though miR-122 was once thought to be
liver-specific, elevated levels of plasma miR-122 have
also been reported in coronary artery stenosis and myo-
cardial infarction29 and cardiogenic shock.30 The cur-
rent study confirmed our previous studies that ischemic
stroke decreased miR-122 in whole blood of rats,8 with
similar findings in whole blood of humans after stroke.9
These findings prompted us to test whether administra-
tion of miR-122 would affect ischemic stroke outcomes.
microRNA mimics and PEG-lysosome
To administer miR-122, we used the commonly used
mimic approach. The miRNA mimics are chemically
modified, double-stranded RNAs that are intended to
‘‘mimic’’ native miRNA which are incorporated into
the RNA-induced silencing complex (RISC), which
then recognizes target mRNAs through base-pairing,
and decreases the target mRNA expression by post-
transcriptional gene silencing.31 The miRNA mimics
are more stable and produce longer lasting effects in
blood and tissues than native miRNA. To achieve
effective intracellular delivery of the miRNA mimic in
vivo, we utilized the polyethylene glycol 2000 (PEG)-
liposome-based miRNA in vivo transfection method.
There is little detectable toxicity or inflammatory
response due to the biodegradable PEG liposome.
The PEG-liposome-conjugated complexes are stable
in serum for at least 16 h. This improves the in vivo
miRNA mimic half-life from minutes to many hours
and enhances miRNA mimic entry into cells.32 The
PEG-liposome-based transfection system produces a
transient elevation of miR-122 after administration,
thus avoiding long lasting or developmental side effects
of transgenic over expression.
Figure 4. miR-122 (2.4mg/kg i.v.) mimic maintains vessel caliber, vWF immunoreactivity, and prevents ICAM-1 induction one day
after MCAO in rats compared to scramble miRNA. Scrambled miRNA mimic and miR-122 mimic were wrapped using PEG-liposomes
prior to i.v. administration after MCAO. Note induction of ICAM1 with scramble miRNA (E) which is blocked by miR-122 mimic (H).
Note decrease in vessel caliber following scramble miRNA (D) which is prevented by miR-122 mimic (G). n¼ 4/group. Scale bars: A–I,
50 mm.
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miR-122 may improve outcome by acting
on leukocytes – not brain
The miR-122 mimic/ PEG-liposome complexes given
intravenously dose dependently elevated miR-122 one
day following MCAO. Though miR-122 mimic at the
lower dose (0.6mg/kg, i.v.) increased the level of miR-
122 in blood after MCAO, these changes were not stat-
istically significant (Figures 1 and 2). However, the low
dose of the (0.6mg/kg, i.v.) miR-122 mimic did signifi-
cantly decrease brain infarction volume after MCAO
(Figure 3). This suggested that the 0.6mg/kg (i.v.)
dose might be right at the threshold for improving
outcomes after MCAO. Indeed, miR-122 mimic at a
four-fold higher dose (2.4mg/kg, i.v.) consistently and
statistically significantly increased the level of miR-122
in blood, improved neurological impairment, and
decreased brain infarction volume after MCAO.
Compared to scramble miRNA-treated MCAO ani-
mals, miR-122 mimic at the lower dose (0.6mg/kg, i.v.)
mostly protected cortex (penumbra) without having
much effect on striatal infarction (core) (Figure 3).
Since the striatal damage mostly contributes to neuro-
logical scores measured in this study, and the striatal
damage was similar in the scramble and miR-122
(0.6mg/kg, i.v.)-treated animals (Figure 3), this may
help explain why the low dose miR-122 mimic
(0.6mg/kg, i.v.) significantly decreased brain infarction
volume after MCAO (Figure 3) while tending to
decrease neurological impairment, but this did not
reach significance (Figure 2). Lastly, even though the
0.6mg/kg iv dose of miR-122 mimic did increase miR-
Figure 5. miR-122 mimic down-regulates genes in blood after MCAO in rats. Scrambled miRNA mimic and miR-122 mimic were
wrapped using PEG-liposomes prior to intravenous administration after MCAO. Upper left panel: miR-122 direct target genes down
regulated 24 h following MCAO which have sequences complementary to miR-122. Upper right panel: miR-122 indirect target genes
down-regulated 24 h following MCAO. The indirect target genes shown are known to be regulated by Vcam1 and/or Nos2- which are
direct miR-122 target genes. Middle panel: top 5 ranked canonical pathways of the miR-122 direct and indirect target genes that were
down-regulated by miR-122 mimic 24h following MCAO. Lower panel: these are mRNAs that were down regulated 24 h following miR-
122 treatment. These genes are not known to be either direct or indirect miR-122 targets. Thus, these represent novel miR-122
indirect target genes that must be regulated by one of the known miR-122 direct target genes. There are two colors of the lined circles
in upper and lower panels: (1) the red lined circled genes were deceased greater than three times; and (2) the black lined circled genes
were decreased ranging from 1.4 through three times. In addition, there are three thicknesses of the lined circles in upper and lower
panels: (1) the small thickness lined circled genes were decreased with p> 0.05; (2) the medium thickness lined circled genes were
decreased with 0.01< p< 0.05; and (3) the large thickness lined circled genes were decreased with p< 0.01. (n¼ 6/group).
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122 blood levels nearly four fold (Figure 1), this was not
statistically significant because of the variability.
Though the low dose of the miR-122 mimic (0.6mg/
kg, i.c.v.) decreased infarct volume, the same dose
injected into the brain ventricles (0.6mg/kg, i.c.v.) did
not decrease infarction volume. Since the intravenous
dose is distributed in 250–300 g of body tissue, while the
ventricular dose is distributed in 2 g of brain, concen-
trations nearly 100 times less in blood improved stroke
outcome whereas concentrations over 100 times greater
in brain did not affect stroke outcome. Therefore, we
postulate that intravenous administration of miR-122
mimic likely acted on peripheral blood leukocytes or
perhaps other blood cells to improve stroke outcomes.
miR-122 expression has previously been reported in
peripheral blood mononuclear cells.33 Also, miR-122
has anti-inflammatory actions in the liver34 and modu-
lates immune genes in zebrafish following LPS
stimulation.35
It is also possible intravenous miR-122 acted on
brain blood vessels. However, if this were the case,
then one has to postulate that intraventricular miR-
122 mimic did not improve stroke outcomes because
it acted on abluminal sides of vessels, whereas intraven-
ous miR-122 mimic acted on luminal sides of vessels
directly on endothelial cells to improve stroke out-
comes. If miR-122 acted directly on endothelium, this
might help explain why miR-122 decreased ICAM-1
expression and maintained vessel integrity. Future stu-
dies will be needed to address these questions.
To examine possible mechanisms by which miR-122
might protect against ischemic stroke, we measured
levels of selected miR-122 target mRNAs. In modeling
miRNA-mRNA interactions, we used the classical/most
commonly encountered model in which miRNAs bind to
complementary sequences in the three prime untrans-
lated regions (30UTRs) of target mRNAs, resulting in
degradation of the target mRNA or suppression of
translation of the target mRNA.4,36,37 The data show
that the miR-122 mimic down-regulated a number of
mRNA in blood after MCAO. Using EGAN and IPA,
we found that miR-122 down-regulated direct and indir-
ect target genes associated with cell adhesion, diapedesis,
leukocyte extravasation, elcosanoid, and atherosclerosis
signaling. These pathways suggest that the miR-122
mimic might modulate cell infiltration after ischemic
stroke, something which can be assessed in future stu-
dies. In addtion, miR-122 acts on other target genes and
pathways that have been associated with stroke out-
comes including Nos2 (neuronal Nos), Chloride intracel-
lular channel 4, Erythropoietin, Aldolase A and calpain
1. It is important to emphasize that all of the possible
miR-122 target mRNA were not examined here, and
which include regulation of iron metabolism,38 mito-
chondria,39 and cholesterol metabolism.40
There are several limitations of the current study.
Future studies will need to examine miR-122 expression
after i.c.v. administration of miR-122 mimic in MCAO
animals, determine how i.c.v. administration affects
miR-122 target gene expression in brain, and to deter-
mine if i.c.v. miR-122 mimic at higher doses could pre-
vent brain damage after MCAO, as it was possible that
miR-122 mimic at the dose (0.6mg/kg, i.c.v.) used in
this study was not high enough to protect brain cells
after MCAO. Future studies will also need to directly
test whether miR-122 mimic modulates gene expression
of leukocytes and/or cerebral endothelial cells. Future
studies will also need to address STAIR criteria for
testing stroke therapeutics including testing both
sexes, testing aged animals, defining the therapeutic
time window, testing in another species and testing in
animals with stroke risk factors. One more limitation is
that miR-122 may or may not directly bind to the target
genes predicted by EGAN. Therefore, future studies
will need to be performed to evaluate miR-122 binding
sites on its target genes using the luciferase reporter
assay system.
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